UK-based drug discovery AdoRx Therapeutics has raised $10 million to fund its work on identifying new cancer therapeutics, in an investment round financed by Epidarex Capital and CRT Pioneer Fund.
AdoRx was founded in 2017 by healthcare investor Epidarex Capital, and has since assembled a group of pharma industry veterans led by Pete Finan, former head of the Novartis Institutes of BioMedical Research UK site.
The company is focusing its efforts on the discovery of new modulators of the adenosine pathway for the treatment of cancer.
Read more: http://www.pharmatimes.com/news/adorx_raises_$10m_for_new_cancer_therapeutics_1241146